Comparative Pharmacology
Head-to-head clinical analysis: BENICAR HCT versus OLMESARTAN MEDOXOMIL AMLODIPINE AND HYDROCHLOROTHIAZIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BENICAR HCT versus OLMESARTAN MEDOXOMIL AMLODIPINE AND HYDROCHLOROTHIAZIDE.
BENICAR HCT vs OLMESARTAN MEDOXOMIL, AMLODIPINE AND HYDROCHLOROTHIAZIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination of an angiotensin II receptor blocker (ARB) and a thiazide diuretic. Olmesartan blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II by selectively antagonizing the AT1 receptor. Hydrochlorothiazide inhibits the sodium-chloride symporter in the distal convoluted tubule, increasing excretion of sodium, chloride, and water, thereby reducing plasma volume.
Olmesartan medoxomil is an angiotensin II receptor blocker (ARB) that selectively blocks AT1 receptors, inhibiting vasoconstriction and aldosterone secretion. Amlodipine is a dihydropyridine calcium channel blocker that inhibits calcium influx across vascular smooth muscle and cardiac muscle, causing vasodilation. Hydrochlorothiazide is a thiazide diuretic that inhibits sodium reabsorption in the distal convoluted tubule, increasing excretion of sodium and water.
One tablet orally once daily. Available strengths: 40 mg olmesartan / 12.5 mg hydrochlorothiazide, 40 mg olmesartan / 25 mg hydrochlorothiazide. Dose may be titrated after 2-4 weeks based on response.
Oral, one tablet once daily. Initial dose: olmesartan 20 mg/amlodipine 5 mg/hydrochlorothiazide 12.5 mg. Titrate based on response, max dose: olmesartan 40 mg/amlodipine 10 mg/hydrochlorothiazide 25 mg daily.
None Documented
None Documented
Olmesartan: Terminal elimination half-life is 10-15 hours, supporting once-daily dosing. Hydrochlorothiazide: Terminal half-life is 5.6-14.8 hours (mean ~10 hours), prolonged in renal impairment.
Olmesartan: terminal half-life 10-15 hours; supports once-daily dosing. Amlodipine: terminal half-life 30-50 hours; allows once-daily dosing with steady state reached after 7-8 days. Hydrochlorothiazide: terminal half-life 6-15 hours; prolonged in renal impairment.
Olmesartan: Approximately 50-65% of absorbed dose excreted in urine (10-20% as unchanged drug, remainder as metabolites), 35-50% in feces via biliary excretion. Hydrochlorothiazide: ≥95% excreted renally as unchanged drug.
Olmesartan: ~40% excreted in urine (10-20% unchanged, rest as metabolites), ~60% in feces via bile. Amlodipine: ~60% excreted in urine (10% unchanged), 20-25% in feces. Hydrochlorothiazide: >95% excreted unchanged in urine.
Category C
Category D/X
ARB + Thiazide Diuretic
ARB